Tests a TheraBionic P1 device in adults with advanced liver cancer
Tests a device in adults with advanced liver cancer after other treatments.
Key facts
- Who runs it
- Barbara Ann Karmanos Cancer Institute
- Where
- Ann Arbor, Bay City, Detroit, Flint, Houston, Lansing, Lapeer, and Mount Pleasant, United StatesSee the 8 sites
- Trial code
- Registry title
- TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
- Status
- Recruiting
- People taking part
- 198 people, planned
- Started
- 20 Oct 2025
- Expected to end
- 31 Aug 2028
- Type of study
- Interventional
- Treatments tested
- TheraBionic P1
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced liver cancer (hepatocellular carcinoma) who have no standard treatment options left and can use the TheraBionic P1 device.
- Age
- 22 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced hepatocellular carcinoma: a liver tumor that cannot have local therapy because of how far it has spread, or that came back after local therapy. The disease must be measurable.
- Earlier treatment
- Have failed at least two lines of therapy, or can no longer have any standard therapy, or cannot tolerate at least two lines of therapy.
Main reasons for not taking part
- Known active second cancer, unless the investigator thinks it will not interfere with the trial
- Taking any other investigational drugs
- Active inflammation, ulcers or other problems in the mouth that could interfere with the device
- Taking calcium channel blockers or similar drugs, unless stopped before treatment
- Breastfeeding, unless breastfeeding is stopped
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patients with advanced hepatocellular carcinoma (HCC) (defined as a liver tumor not eligible for local therapies given the extent of disease or a livor tumor that recurred after local therapy)
- Patients who have failed at least two lines of therapy* or who are no longer eligible for any line of standard therapy or who are intolerant to at least two lines of therapy
- Patients with evaluable disease
- Patients must be ≥ 22 years old and must be able to understand and sign an informed consent
- Female patients of childbearing potential and their partners and male patients must agree to use adequate contraception during the period of study treatment
- Patients with a life expectancy of at least 3 months
Who cannot take part
- Patients taking any other investigational drugs
- Patients with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints
- Patients with a known severe (e.g., anaphylactic) allergy to nickel
- Patients receiving calcium channel blockers and any agent blocking L-type of T-type Voltage Gated Calcium Channels, e.g., amlodipine, nifedipine, ethosuximide, ascorbic acid (vitamin C), etc. unless their medical treatment is discontinued to prior to treatment on study. Patients must agree to abstain from using calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels for the duration of treatment on study
- Patients with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of the device
- Patients who are breastfeeding. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued
- Patients that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device for the prescribed period and frequency (three 60-minute treatments in the morning, middle of the day, and evening)
Where in United States
- University of MichiganAnn Arbor, United StatesContact: Vaibhav Sahai, MDTaking people
- Karmanos Cancer Institute at McLaren Bay RegionBay City, United StatesContact: Anthony F Shields, M.D.Taking people
- Karmanos Cancer InstituteDetroit, United StatesContact: Anthonly F Shields, M.D.Taking people
- Karmanos Cancer Institute at McLaren FlintFlint, United StatesContact: Anthony F Shields, M.D.Taking people
- University of Texas M.D. Anderson Cancer CenterHouston, United StatesContact: Kim RossTaking people
- Karmanos Cancer Institute at McLaren Greater LansingLansing, United StatesContact: Anthony F Shields, M.D.Taking people
- Karmanos Cancer Institute at McLaren Lapeer RegionLapeer, United StatesContact: Anthony F Shields, M.D.Taking people
- Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer CenterMount Pleasant, United StatesContact: Anthony F Shields, M.D.Taking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are:
Read full original descriptionShow less
* will the TheraBionic P1 device affect overall survival in advance HCC * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device
The group in the trial
- TheraBionic P1 deviceTreatment being tested
Self administered Amplitude-modulated electromagnetic fields three times daily
Treatment: TheraBionic P1
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- TheraBionic P1 Device for Patients With Advanced Hepatocellular Carcinoma (HCC) Who Fail First and Second Line Therapy
- Plain-language title
- Tests a TheraBionic P1 device in adults with advanced liver cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 November 2026